TEST BANK FOR Pharmacotherapeutics for Advanced Practice: A Practical Approach Fifth, North American Edition by Virginia by Poole Arcangelo, Andrew M. Peterson PharmD ALL CHAPTERS COVERED YOUR ULTIMATE GUIDE 100% VERIFIED A+ GRADE ASSURED!!!!!! NEW LATE

Test Bank For Pharmacotherapeutics For Advanc
KJHN KJHN KJHN KJHN KJHN




ed Practice A Practical Approach 5th Editi
KJHN KJHN KJHN KJHN KJHN KJHN




on

, KJ
lOM




HN oARc




KJH
KJHN KJHNNKJHN
lOM oARc
KJ
PSD|
PSD|
3013804




HN 3013804




Chapter 1 Issues for the Practitioner
KJHN KJHN KJHN KJHN KJHN KJHN in Drug Therapy
KJHN KJHN




MULTIPLEKJHNCHOICE

1. NurseK J H N practitionerK J H N prescriptiveK J H N authorityK J H N isK J H N regulatedK J H N by:
A. TheKJ HN NationalK J H N CouncilK J H N ofK J H N StateK J H N BoardsK J H N ofKJHN Nursing
B. TheKJ H N U.S.K J H N DrugK J H N EnforcementK J H N Administration
C. TheKJ HN StateKJHN BoardK J H N ofKJHNNursingK J H N forK J H N eachK J H N state
D. TheKJ H N StateKJHNBoardK J H N ofKJHN Pharmacy
ANS:K J H N C PTS:K J H N 1

2. PhysicianK J H N AssistantK J H N (PA)K J H N prescriptiveK J H N authorityK J H N isK J H N regulatedK J H N by:
A. TheKJ HN NationalK J H N CouncilK J H N ofK J H N StateKJ H N BoardsK J H N ofK J H N Nursing
B. TheKJ H N U.S.K J H N DrugK J H N EnforcementK J H N Administration
C. TheKJ H N StateKJHNBoardK J H N ofKJHN Nursing
D. TheKJ HN StateKJHNBoardK J H N ofKJ H N MedicalK J H N Examiners

ANS:K J H N D PTS:K J H N 1

3. ClinicalK J H N judgmentK J H N inK J H N prescribingK J H N includes:
A. FactoringKJHN inKJ H N theKJ HN costK J H N toKJ H N theKJ H N patientK J H N ofKJHNtheK J H N medicationK J H N prescribed
B. AlwaysK J H N prescribingK J H N theK J H N newestK J H N medicationK J H N availableK J H N forK J H N theKJ HN diseaseK J H N pr
ocess
C. HandingK J H N outK J H N drugK J H N samplesKJHNtoKJ H N poorK J H N patients
D. PrescribingKJHNallK J H N genericK J H N medicationsKJ H N toK J H N cutK J H N costs
ANS:K J H N A PTS:K J H N 1

4. CriteriaK J H N forK J H N choosingKJ HN anK J H N effectiveKJ HN drugK J H N forKJHN aK J H N disorderK J H N include:
A. AskingKJHN theKJHN patientK J H N whatKJ HN drugKJHNtheyKJHNthinkK J H N wouldK J H N workK J H N bestK J H N forKJ HN them
B. ConsultingK J H N nationallyK J H N recognizedK J H N guidelinesK J H N forK J H N diseaseK J H N management
C. PrescribingK J H N medicationsK J H N thatK J H N areKJ H N availableKJ HN asK J H N samplesK J H N beforeK J H N writingKJ HN a
K J H N prescription

D. FollowingKJHNU.S.KJHNDrugKJHNEnforcementKJHNAdministrationKJHN(DEA)KJHNgui
delinesKJHNforK J H N prescribing
ANS:K J H N B PTS:K J H N 1

5. NurseK J H N practitionerK J H N practiceK J H N mayK J H N thriveKJHN underK J H N health-careKJHN reformK J H N dueKJ H N to:
A. TheKJHNdemonstratedKJHNabilityKJHNofKJHNnurseKJHNpractitionersKJHNtoKJHNcontrolKJHNcostsKJHNand
KJHNimproveKJHNpatientK J H N outcomes

B. TheKJ H N factK J H N thatK J H N nurseKJ HN practitionersK J H N willK J H N beKJHN ableKJHNtoK J H N practiceKJ HN independentl
y
C. TheKJHNfactKJHNthatKJHNnurseKJHNpractitionersKJHNwillKJHNhaveKJHNfullKJHNreimbursementKJHN
underKJHNhealth-careK J H N reform
D. TheKJHNabilityK J H N toK J H N shiftKJ H N accountabilityK J H N forK J H N MedicaidKJHNtoKJ HN theKJHN stateKJ H N level
ANS:K J H N A PTS:K J H N 1

, KJ
lOM




HN oARc




KJH
N KJ PSD|




HN 3013804




Chapter 2.Pharmacokinetic
KJHN KJHN BasisKJHNof Therapeutics
KJHN KJHNand KJHNPharmacodynamic


MULTIPLEKJHNCHOICE

1. AKJHNpatient’sKJHNnutritionalK J H N intakeKJHNandKJHNlabKJHNworkKJHNreflectsKJHNhypoalbuminemia.KJ
HNThisKJHNisKJHNcriticalKJHNtoKJHNprescribingK J H N because:

A. DistributionK J H N ofKJ HN drugsKJHNtoKJHNtargetK J H N tissueK J H N mayK J H N beK J H N affected
B. TheKJ HN solubilityK J H N ofKJHNtheKJ HN drugK J H N willK J H N notK J H N matchKJHNtheKJ HN siteKJ HN ofKJHNabsorption
C. ThereK J H N willK J H N beKJHNlessK J H N freeKJ H N drugKJHNavailableKJ HN toK J H N generateKJHNanK J H N effect
D. DrugsK J H N boundK J H N toK J H N albuminKJ HN areKJHNreadilyK J H N excretedK J H N byKJ HN theKJHNkidney
ANS:K J H N A PTS:K J H N 1

2. DrugsKJ HN thatK J H N haveKJHNaK J H N significantK J H N first-passKJ HN effect:
A. MustK J H N beKJHN givenKJ H N byK J H N theK J H N enteralK J H N (oral)KJ H N routeKJHNonly
B. BypassKJ HN theK J H N hepaticK J H N circulation
C. AreKJHNrapidlyK J H N metabolizedK J H N byKJHNtheKJHNliverK J H N andK J H N mayK J H N haveKJ HN littleKJHNifKJ H N anyK J H N
desiredK J H N action
D. AreK J H N convertedK J H N byK J H N theKJ H N liverKJHN toK J H N moreKJHNactiveKJHNandK J H N fat-solubleK J H N forms
ANS:K J H N C PTS:K J H N 1

3. TheKJHNrouteKJ H N ofKJHNexcretionK J H N ofKJHNaK J H N volatileKJ HN drugK J H N willK J H N likelyK J H N be:
A. TheKJHNkidneys
B. TheKJHNlungs
C. TheKJ HN bileKJHNandK J H N feces
D. TheKJHN skin
ANS:K J H N B PTS:K J H N 1

4. MedroxyprogesteroneKJHN(DepoK J H N Provera)K J H N isKJHNprescribedKJHNIMKJHNtoKJHNcreateKJHNaK J H N sto
rageKJHNreservoirK J H N ofKJHNtheKJHNdrug.KJHNStorageKJHNreservoirs:
A. AssureKJHNthatKJHN theK J H N drugK J H N willKJ HN reachK J H N itsKJHN intendedK J H N targetK J H N tissue
B. AreKJHN theKJHNreasonK J H N forK J H N givingK J H N loadingK J H N doses
C. IncreaseK J H N theKJ H N lengthK J H N ofKJHNtimeKJ H N aK J H N drugKJHN isK J H N availableKJHN andK J H N active
D. AreK J H N mostK J H N commonK J H N inK J H N collagenKJ H N tissues
ANS:K J H N C PTS:K J H N 1

5. TheKJHN NPK J H N choosesKJHNtoK J H N giveK J H N cephalexinK J H N everyKJHN8K J H N hoursK J H N basedK J H N onKJHN knowledg
eKJ HN ofKJ HN theK J H N drug’s:
A. PropensityKJHN toK J H N goK J H N toKJHNtheKJHNtargetK J H N receptor
B. BiologicalK J H N half-life
C. Pharmacodynamics
D. SafetyKJHN andK J H N sideKJ HN effects
ANS:K J H N B PTS:K J H N 1

6. AzithromycinKJHNdosingK J H N requiresKJHNtheKJHNfirstKJHNday’sKJHNdoseKJHNbeKJHNtwiceKJHNthoseKJHNofKJHNt
heKJHNotherK J H N 4KJHNdaysKJHNofKJHNtheKJHNprescription.KJHNThisKJHNisKJHNconsideredK J H N aKJHNloadingK J
H N dose.K J H N AKJHNloadingK J H N dose:

A. RapidlyKJ HN achievesK J H N drugK J H N levelsK J H N inK J H N theK J H N therapeuticK J H N range
B. RequiresK J H N fourKJHN toKJ H N fiveK J H N half-livesKJ HN toKJHN attain
C. IsKJ HN influencedK J H N byKJHN renalK J H N function

, KJ
lOM




HN oARc




KJH
N KJ PSD|




HN 3013804




D. IsKJHN directlyK J H N relatedK J H N toKJ HN theKJ HN drugK J H N circulatingKJHN toKJ H N theKJ HN targetK J H N tissues
ANS:K J H N A PTS:K J H N K J H N 1

7. TheKJHNpointKJHNinKJHNtimeKJHNonKJHNtheK J H N drugK J H N concentrationK J H N curveKJHNthatK J H N indicatesKJHNtheKJ
HNfirstK J H N signKJHNofKJHNaK J H N therapeuticKJHNeffectKJHNisKJHNthe:

A. MinimumK J H N adverseK J H N effectK J H N level
B. PeakK J H N ofKJHNaction
C. OnsetK J H N ofKJHNaction
D. TherapeuticK J H N range

ANS:K J H N C PTS:K J H N 1

8. PhenytoinK J H N requiresKJHN aK J H N troughK J H N levelK J H N beK J H N drawn.K J H N PeakK J H N andKJHN troughK J H N levelsKJHNar
eK J H N done:
A. WhenKJHN theKJ H N drugK J H N hasKJHN aK J H N wideKJ H N therapeuticK J H N range
B. WhenKJHNtheKJHN drugK J H N willK J H N beKJHNadministeredK J H N forK J H N aK J H N shortKJHN timeK J H N only
C. WhenKJHN thereKJHNisKJHN aK J H N highK J H N correlationK J H N betweenKJHN theK J H N doseK J H N andK J H N saturationK J H N
ofKJHNreceptorK J H N sites
D. ToKJHNdetermineKJHNifK J H N aK J H N drugKJ HN isK J H N inKJHN theKJHN therapeuticK J H N range
ANS:K J H N D PTS:K J H N 1

9. AKJHNlaboratoryKJHNresultKJHNindicatesKJHNtheKJHNpeakKJHNlevelKJHNforKJHNaK J H N drugKJHNisKJHNabo
veKJHNtheKJHNminimumKJHNtoxicKJHNconcentration.KJHNThisKJHNmeansKJHNthatKJHNthe:
A. ConcentrationK J H N willK J H N produceK J H N therapeuticK J H N effects
B. ConcentrationK J H N willK J H N produceKJ H N anK J H N adverseK J H N response
C. TimeK J H N betweenK J H N dosesK J H N mustK J H N beK J H N shortened
D. DurationKJ H N ofKJHNactionK J H N ofKJHNtheK J H N drugKJHNisKJHN tooK J H N long
ANS:K J H N B PTS:K J H N 1

10. DrugsK J H N thatK J H N areKJHNreceptorK J H N agonistsK J H N mayK J H N demonstrateK J H N whatK J H N property?
A. IrreversibleK J H N bindingKJ HN toK J H N theKJ H N drugK J H N receptorK J H N site
B. Up-regulationK J H N withK J H N chronicK J H N use
C. DesensitizationK J H N orK J H N down-regulationK J H N withK J H N continuousK J H N use
D. InverseK J H N relationshipK J H N betweenK J H N drugK J H N concentrationK J H N andK J H N drugK J H N action
ANS:K J H N C PTS:K J H N 1

11. DrugsK J H N thatKJ H N areKJHN receptorK J H N antagonists,K J H N suchK J H N asKJ HN betaK J H N blockers,K J H N mayK J H N cause:
A. Down-regulationK J H N ofKJHN theK J H N drugK J H N receptor
B. AnK J H N exaggeratedK J H N responseK J H N ifKJHNabruptlyK J H N discontinued
C. PartialK J H N blockadeK J H N ofKJHNtheK J H N effectsK J H N ofKJHNagonistK J H N drugs
D. AnK J H N exaggeratedK J H N responseK J H N toK J H N competitiveK J H N drugK J H N agonists
ANS:K J H N B PTS:K J H N 1

12. FactorsKJ H N thatK J H N affectK J H N gastricK J H N drugK J H N absorptionK J H N include:
A. LiverK J H N enzymeKJHN activity
B. Protein-bindingK J H N propertiesK J H N ofKJHN theK J H N drugK J H N molecule
C. LipidK J H N solubilityK J H N ofKJHNtheKJHN drug
D. AbilityKJ HN toKJ HN chewKJ HN andK J H N swallow
ANS:K J H N C PTS:K J H N 1